Livzon Pharmaceutical Group Inc. (SHE:000513)

Market Cap	28.12B
Revenue (ttm)	11.75B
Net Income (ttm)	2.09B
Shares Out	892.78M
EPS (ttm)	2.29
PE Ratio	15.29
Forward PE	14.09
Dividend	1.10 (3.12%)
Ex-Dividend Date	Jul 8, 2024

Volume	4,074,307
Average Volume	4,452,059
Open	34.73
Previous Close	35.09
Day's Range	34.73 - 35.25
52-Week Range	32.94 - 44.72
Beta	0.42
RSI	53.83
Earnings Date	Apr 28, 2025

About SHE:000513

Livzon Pharmaceutical Group Inc. researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients and intermediates in the People’s Republic of China. The company offers drug preparation products, including Ilaprazole enteric coated tablets to treat duodenal ulcers and reflux esophagitis; Laprazole sodium for injection to treat peptic ulcer hemorrhage; Leuprorelin Acetate Microspheres for injection to treat endometriosis, hysteromyoma, premenopausal breast and prostate cancer, and central precoci...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1985
• Employees: 9,067
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 000513

Financial Performance

In 2024, SHE:000513's revenue was 11.81 billion, a decrease of -4.97% compared to the previous year's 12.43 billion. Earnings were 2.06 billion, an increase of 5.50%.